The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Abstract
Objective: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks. Methods: Using 2:1 randomization, 439 PPMS patients received two 1,000mg intravenous rituximab or placebo infusions every 24 weeks, through 96 weeks (4 courses). The primary endpoint was time to confirmed disease progression (CDP), a prespecified increase in Expanded Disability Status Scale sustained for 12 weeks. Secondary endpoints were change from baseline to week 96 in T2 lesion volume and total brain volume on magnetic resonance imaging scans. Results: Differences in time to CDP between rituximab and placebo did not reach significance (96‐week rates: 38.5% placebo, 30.2% rituximab; p = 0.14). From baseline to week 96, rituximab patients had less ( p < 0.001) increase in T2 lesion volume; brain volume change was similar ( p = 0.62) to placebo. Subgroup analysis showed time to CDP was delayed in rituximab‐treated patients aged <51 years (hazard ratio [HR] = 0.52; p = 0.010), those with gadolinium‐enhancing lesions (HR = 0.41; p = 0.007), and those aged <51 years with gadolinium‐enhancing lesions (HR = 0.33; p = 0.009) compared with placebo. Adverse events were comparable between groups; 16.1% of rituximab and 13.6% of placebo patients reported serious events. Serious infections occurred in 4.5% of rituximab and <1.0% of placebo patients. Infusion‐related events, predominantly mild to moderate, were more common with rituximab during the first course, and decreased to rates comparable to placebo on successive courses. Interpretation: Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B‐cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions. Ann Neurol 2009;66:460–471
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
Self-citationPrimary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Godbout, J. P., Chen, J., Abraham, J., Richwine, A. F., Berg, B. M., Kelley, K. W., & Johnson, R. W. (2005) · The FASEB Journal · doi:10.1096/fj.05-3776fje · Cited by 813
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Self-citationRituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Self-citation
Cited by
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationNew Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationFilippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, R., & Trapp, B. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.005 · Cited by 457
Lublin, F., Miller, D. H., Freedman, M. S., Cree, B. A. C., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H.-P., Montalban, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Self-citationRituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Traboulsee, A., Simon, J. H., Stone, L., Fisher, E., Jones, D. E., Malhotra, A., Newsome, S. D., Oh, J., Reich, D. S., Richert, N., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4539 · Cited by 340
Self-citationKappos, L., Hartung, H.-P., Freedman, M. S., Boyko, A., Radü, E. W., Mikol, D. D., Lamarine, M., Hyvert, Y., Freudensprung, U., Plitz, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70028-6 · Cited by 338
Self-citationWeber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A. J., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 318
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00577 · Cited by 310
Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 302
Self-citationProgressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31320-4 · Cited by 298
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
Absinta, M., Vuolo, L., Rao, A., Nair, G., Sati, P., Cortese, I. C. M., Ohayon, J., Fenton, K., Reyes-Mantilla, M. I., Maric, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001587 · Cited by 296
Self-citationTargeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Neurodegeneration in multiple sclerosis and neuromyelitis optica
Kawachi, I., & Lassmann, H. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313300 · Cited by 283
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Self-citationConvalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Hueso, T., Pouderoux, C., Péré, H., Beaumont, A.-L., Raillon, L.-A., Ader, F., Chatenoud, L., Eshagh, D., Szwebel, T.-A., Martinot, M., et al. (2020) · Blood · doi:10.1182/blood.2020008423 · Cited by 281
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
B cells and antibodies in multiple sclerosis pathogenesis and therapy
Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.203 · Cited by 267
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Self-citationSystematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Eshaghi, A., Young, A. L., Wijeratne, P. A., Prados, F., Arnold, D. L., Narayanan, S., Guttmann, C. R. G., Barkhof, F., Alexander, D. C., Thompson, A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22265-2 · Cited by 257
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Eggers, E. L., Michel, B. A., Wu, H., Wang, S.-Z., Bevan, C. J., Abounasr, A., Pierson, N. S., Bischof, A., Kazer, M., Leitner, E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92724 · Cited by 93
“While anti-CD20 antibodies appear to be moderately effective in progressive MS (6, 46), onset of secondary progression may not be prevented if treatment is started too late (47).”
BackgroundSelf-citationThe tension between early diagnosis and misdiagnosis of multiple sclerosis
Solomon, A. J., & Corboy, J. R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.106 · Cited by 89
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Retinal and brain microglia in multiple sclerosis and neurodegeneration
Choi, S., Guo, L., & Cordeiro, M. F. (2021) · Cells · doi:10.3390/cells10061507 · Cited by 63
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Immune-mediated processes in neurodegeneration: where do we stand?
Fakhoury, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8052-0 · Cited by 43
DiSano, K. D., Royce, D. B., Gilli, F., & Pachner, A. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01821 · Cited by 30
Melanocortins, Melanocortin Receptors and Multiple Sclerosis
Lisak, R., & Benjamins, J. (2017) · Brain Sciences · doi:10.3390/brainsci7080104 · Cited by 27
Potential role of regulatory B cells in immunological diseases
Valizadeh, A., Sanaei, R., Rezaei, N., Azizi, G., Fekrvand, S., Aghamohammadi, A., & Yazdani, R. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.08.004 · Cited by 16
Metadata
- Authors
- Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P., Smith, C. H., & OLYMPUS trial group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-10
- Volume
- 66
- Issue
- 4
- Pages
- 460-471
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2107008240
- Cited by
- 934
- References
- 34
- FWCI
- 31.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.